Evaluation and medical management of benign prostatic hyperplasia

Mayo Clinic Proceedings

Volumn 80, Issue 10, 2005, Pages 1356-1362

  Beckman, Thomas J ^a   Mynderse, Lance A ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SABAL EXTRACT; SILDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; TAMSULOSIN; TERAZOSIN; VARDENAFIL;

AGING; ANAMNESIS; BLADDER NECK STENOSIS; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DIGITAL RECTAL EXAMINATION; DIZZINESS; EDEMA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; GYNECOMASTIA; HEADACHE; HEART PALPITATION; HERBAL MEDICINE; HUMAN; HYPOTENSION; KIDNEY DISEASE; LIBIDO DISORDER; NEUROLOGIC DISEASE; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PATIENT REFERRAL; PHYSICAL EXAMINATION; PROSTATE HYPERTROPHY; SYMPTOM; URINALYSIS; URINARY TRACT INFECTION; URINE RETENTION; URODYNAMICS; UROFLOWMETRY;

EID: 25844524640     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/80.10.1356     Document Type: Conference Paper

References (45)

1. Arrighi HM, Metter EJ, Guess HA, Fozzard JL. Natural history of benign prostatic hyperplasia and risk of prostatectomy: The Baltimore Longitudinal Study of Aging. Urology. 1991;38(1, suppl):4-8.
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-479.
3. McNeal JE. The prostate gland: morphology and pathobiology. Monogr Urol. 1983;4:3-33.
4. Barry M, Roenrbom C. Management of benign prostatic hyperplasia. Annu Rev Med. 1997;48:177-189.
5. Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol. 1999;161:1174-1179.
6. Roberts RO, Jacobsen SJ, Jacobson DJ, Rhodes T, Girman CJ, Lieber MM. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol. 2000;163:107-113.
7. Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol. 1996;155:595-600.
8. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol. 1997;158:481-487.
9. Clarke HS Jr. Benign prostatic hyperplasia. Am J Med Sci. 1997;314: 239-244.
10. Barry MJ, Cockett AT, Holtgrewe HL, McConnell JD, Sihelnik SA, Winfield HN. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol. 1993;150(2, pt 1):351-358.
11. Lepor H, Nieder A, Feser J, O'Connell C, Dixon C. Total prostate and transition zone volumes, and transition zone index are poorly correlated with objective measures of clinical benign prostatic hyperplasia. J Urol. 1997;158:85-88.
12. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003), chapter 1: diagnosis and treatment recommendations. J Urol. 2003;170(2, pt 1):530-547.
13. Chapple CR. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int. 2004;94:738-744.
14. de la Rosette JJ, van der School DK, Debruyne FM. Recent developments in guidelines on benign prostatic hyperplasia. Curr Opin Urol. 2002;12:3-6.
15. Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate. 1990;17:241-246.
16. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:199-248.
17. Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:141-160.
18. Walsh PC, Retik AB, Vaughan ED Jr, et al, eds. Campbell's Urology. 8th ed. Philadelphia, Pa: WB Saunders Co; 2002.
19. Su L, Guess HA, Girman CJ, et al. Adverse effects of medications on urinary symptoms and flow rate: a community-based study. J Clin Epidemiol. 1996;49:483-487.
20. Barry MJ, Fowler FJ Jr, O'Leary MP, et al, Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148:1549-1557.
21. Coley CM, Barry MJ, Fleming C, Mulley AG. Clinical guideline, part 1: early detection of prostate cancer, part 1: prior probability and effectiveness of tests. Ann Intern Med. 1997;126:394-406.
22. Roehrbom CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53:581-589.
23. Pruthi RS. The dynamics of prostate-specific antigen in benign and malignant diseases of the prostate. BJU Int. 2000;86:652-658.
24. Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE. Ejaculation increases the serum prostate-specific antigen concentration. Urology 1996;47:511-516.
25. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet. 1994;344:1594-1598.
26. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995;274:1214-1220.
27. Kochanska-Dziurowicz AA, Mielniczuk MR, Stojko A, Kaletka J. The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer. Br J Urol. 1998;81:834-838.
28. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215-2220.
29. Eaton CL. Aetiology and pathogenesis of benign prostatic hyperplasia. Curr Opin Urol. 2003;13:7-10.
30. 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999;36:1-13.
31. McVary KT, McKehna KE. The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidence. Curr Urol Rep. 2004;5:251-257.
32. McConnell JD, Bruskewitz R, Walsh P, et al, Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998;338:557-563.
33. Abrams P, Schafer W, Tammela TL, et al, Finasteride Urodynamics Study Group. Improvement of pressure flow parameters with finasteride is greater in men with large prostates. J Urol. 1999;161:1513-1517.
34. Gormley GJ, Stoner E, Bruskewitz RC, et al, Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 1992;327:1185-1191.
35. Laguna P, Alivizatos G. Prostate specific antigen and benign prostatic hyperplasia. Curr Opin Urol. 2000;10:3-8.
36. Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997;282:1496-1502.
37. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, ARIA3001, ARIA3002, and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434-441.
38. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia. Eur Urol. 2000;37:367-380.
39. Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol. 2004;6(suppl 9):S31-S39.
40. Andriole GL, Kirby R. Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003;44:82-88.
41. McConnell JD, Roehrborn CG, Bautista OM, et al, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387-2398.
42. Buck AC. Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? mechanisms of action. J Urol. 2004;172(5, pt 1):1792-1799.
43. Gerber GS. Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol. 2000;163:1408-1412.
44. Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate. 1996;29:231-240.
45. Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology. 2000;55:533-539.